114 related articles for article (PubMed ID: 8187012)
1. Economic analysis in phase III clinical cancer trials.
Bennett CL; Armitage JL; Buchner D; Gulati S
Cancer Invest; 1994; 12(3):336-42. PubMed ID: 8187012
[TBL] [Abstract][Full Text] [Related]
2. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
[TBL] [Abstract][Full Text] [Related]
3. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis during phase III clinical trials: who, what, when, where, and why?
Bennett CL; Westerman IL
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):169-75. PubMed ID: 8608049
[TBL] [Abstract][Full Text] [Related]
6. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
Bennett CL; Golub R; Waters TM; Tallman MS; Rowe JM
Cancer Invest; 1997; 15(3):227-36. PubMed ID: 9171857
[TBL] [Abstract][Full Text] [Related]
7. Factors to consider when designing phase III clinical trials involving economic evaluations.
van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
[TBL] [Abstract][Full Text] [Related]
8. Economic analyses in clinical trials for cooperative groups: operational considerations.
Bennett CL; Waters TM
Cancer Invest; 1997; 15(5):448-53. PubMed ID: 9316627
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?
Bennett CL; Weinberg PO; Golub RM
Semin Hematol; 1999 Jan; 36(1 Suppl 2):26-9. PubMed ID: 9930555
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis alongside clinical trials. Revisiting the methodological issues.
Drummond MF; Davies L
Int J Technol Assess Health Care; 1991; 7(4):561-73. PubMed ID: 1778701
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomics: an emerging discipline.
Letizia C
Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
[TBL] [Abstract][Full Text] [Related]
14. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.
Mauskopf J; Schulman K; Bell L; Glick H
Pharmacoeconomics; 1996 Mar; 9(3):264-77. PubMed ID: 10160101
[TBL] [Abstract][Full Text] [Related]
15. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial.
Schulman KA; Glick H; Buxton M; Sculpher M; Backhouse M; Bell L; Eisenberg JM
Control Clin Trials; 1996 Aug; 17(4):304-15. PubMed ID: 8889345
[TBL] [Abstract][Full Text] [Related]
16. Health Economics Unit achievements.
Crott R; Neymark N
Eur J Cancer; 2002 Mar; 38 Suppl 4():S147-50. PubMed ID: 11858982
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials: are they a good buy?
Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
[TBL] [Abstract][Full Text] [Related]
18. Measuring the incremental cost of clinical cancer research.
Goldman DP; Schoenbaum ML; Potosky AL; Weeks JC; Berry SH; Escarce JJ; Weidmer BA; Kilgore ML; Wagle N; Adams JL; Figlin RA; Lewis JH; Cohen J; Kaplan R; McCabe M
J Clin Oncol; 2001 Jan; 19(1):105-10. PubMed ID: 11134202
[TBL] [Abstract][Full Text] [Related]
19. Reducing the costs of phase III cardiovascular clinical trials.
Eisenstein EL; Lemons PW; Tardiff BE; Schulman KA; Jolly MK; Califf RM
Am Heart J; 2005 Mar; 149(3):482-8. PubMed ID: 15864237
[TBL] [Abstract][Full Text] [Related]
20. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
